Romark, a research-based pharmaceutical company, has started a phase three clinical trial of its investigational new drug candidate, NT-300, intended for the treatment of mild or moderate COVID-19, it was reported on Tuesday.
The trial is to study up to 800 subjects, twelve years of age and older, with fever and respiratory symptoms consistent with COVID-19. The subjects will be administered either NT-300 or placebo twice daily for five days.
The study's primary endpoint is the decrease in the time to sustained response compared with placebo, and the secondary endpoint is a decrease in the rate of progression to severe COVID-19 illness compared with placebo.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax